Adverse Reactions (continued)

Postmarketing Experience
Several additional adverse reactions were identified during the post-approval use of IMPLANON® (etonogestrel implant). Because these reactions are reported voluntarily from a population of uncertain size, it is not possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

- **Gastrointestinal disorders**: constipation, diarrhea, flatulence, vomiting.
- **General disorders and administration site conditions**: edema, fatigue, implant site reaction, pyrexia.
- **Immune system disorders**: anaphylactic reactions
- **Infections and infestations**: rhinitis, urinary tract infection.
- **Investigations**: clinically relevant rise in blood pressure, weight decreased.
- **Metabolism and nutrition disorders**: increased appetite.
- **Musculoskeletal and connective tissue disorders**: arthralgia, musculoskeletal pain, myalgia.
- **Nervous system disorders**: convulsions, migraine, somnolence.
- **Pregnancy, puerperium and perinatal conditions**: ectopic pregnancy.
Adverse Reactions (continued)

Other adverse reactions identified during the post-approval use of IMPLANON® (etonogestrel implant) include:

- **Psychiatric disorders**: anxiety, insomnia, libido decreased.
- **Renal and urinary disorders**: dysuria.
- **Reproductive system and breast disorders**: breast discharge, breast enlargement, ovarian cyst, pruritus genital, vulvovaginal discomfort.
- **Skin and subcutaneous tissue disorders**: angioedema, aggravation of angioedema and/or aggravation of hereditary angioedema, alopecia, chloasma, hypertrichosis, pruritus, rash, seborrhea, urticaria.
- **Vascular disorders**: hot flush.

Complications related to insertion or removal of the non-radiopaque etonogestrel implant reported include: bruising, slight local irritation, pain or itching, fibrosis at the implant site, paresthesia or paresthesia-like events, scarring and abscess.